The previous posts re COVID-19 “vaccine” adverse events have only reported figures from the US. This post includes figures from Europe, particularly the European Economic Area (EEA). Please note the different dates.
According to the Vaccine Adverse Event Reporting System (VAERS): as of 8 April 2021, there have been 68,347 adverse events reported for all COVID-19 “vaccines” in the US. This includes 2,602 deaths (3.8% of reported adverse events).
As of 8 April 2021, 174.88 million doses have been administered in the US. This figure is for doses, not the number of vaccinees since some people require two doses. Below is some back-of-the-envelope math.
68,347 adverse events for 174,880,000 doses: ~39.1 adverse events per 100,000 doses. Or, to put it differently: 1 adverse event per 2,559 doses.
According to the European Database of Suspected Adverse Drug Reaction Reports, the below are the number of reported adverse events with their corresponding “vaccine” as of 17 April 2021 in the EEA:
Astrazeneca – 66,612.
Moderna – 9,119.
Pfizer-Biontech (Tozinameran) – 116,244.
The reports can be called up at www.adrreports.eu/en/background.html. Other vaccines have been used but at significantly lower numbers.
As of 17 April 2021, the below are the doses administered in the EEA:
Astrazeneca – 29,688,800.
Moderna – 10,913,600.
Pfizer-Biontech (Tozinameran) – 80,639,237.
Below are some back-of-the-envelope calculations.
Astrazeneca – 66,612 adverse events for 29,688,800 doses: ~224.3 adverse events per 100,000 doses, or 1 adverse event per 446 doses.
Moderna – 9,119 adverse events for 10,913,600 doses: ~83.6 adverse events per 100,000 doses, or 1 adverse event per 1,196 doses.
Pfizer-Biontech (Tozinameran) – 116,244 adverse events for 80,639,237 doses: ~144.1 adverse events per 100,000 doses, or 1 adverse event per 694 doses.
Compare the above to the supposedly safe MMR vaccine: ~5 adverse events per 100,000 doses or ~1 adverse event per 20,000 doses.
I cannot explain the significant differences between the “vaccines” and the difference between the US and European figures. I suspect it is due to the personal choice of each recipient and medical professional on whether to report the issues, and perhaps the partially subjective nature of what is considered an adverse event (i.e. some people are simply more tolerant to less serious effects.)
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!